Healthcare Industry News: Silver in situ Hybridization
News Release - March 8, 2007
VMSI Launches Automated HER2 Silver for Breast Cancer Pathology
TUCSON, AZ--(Healthcare Sales & Marketing Network)--Mar 8, 2007 -- Ventana Medical Systems, Inc. (NasdaqGS:VMSI ) today announced the launch of its HER2 Silver in situ Hybridization (SISH) technology for use in the European, Canadian, Asian, and Australian markets. HER2 SISH release is expected early 2008 for use in the United States pending FDA approval."We are committed to providing pathologists with access to the latest technological advances in breast cancer pathology and prognostics," commented Chris Gleeson, President and Chief Executive Officer of Ventana. "Our continued focus on scientific innovation in the area of automation and life science chemistry has resulted in the introduction of this outstanding product."
"This ground breaking technology offers pathologists a substantial improvement over current fluorescent methodologies to quickly determine which patients will respond to Herceptin® (Trastuzumab) therapy," said Thomas Grogan, M.D., Ventana's Founder and Chief Medical Officer.
HER2 SISH is the only fully automated chromogenic in situ hybridization assay for HER2 gene and chromosome 17 (Chr17) detection. Precise chromogenic signals are detected through the use of advanced silver deposition technology. The HER2 SISH method is performed in less than half the time required for current FDA approved fluorescent technologies thereby allowing for same day results. Results and morphological significance can be easily interpreted by pathologists using conventional bright field microscopy.
About Ventana
Ventana develops, manufactures, and markets instrument/reagent systems that automate slide preparation and staining in clinical histology and drug discovery laboratories worldwide. Ventana's clinical systems are important tools used in the diagnosis and treatment of cancer and infectious diseases. Ventana's drug discovery systems are used to accelerate the discovery of new drug targets and evaluate the safety of new drug compounds.
Visit the Ventana Medical Systems, Inc. website at www.ventanamed.com.
SAFE HARBOR STATEMENT
This press release contains certain forward-looking statements within the meaning of the Federal Securities laws. These forward-looking statements include, but are not limited to, statements regarding the marketing of products, product development, and market acceptance of Ventana products. These forward-looking statements are subject to numerous risks and uncertainties, and actual results may vary materially. A full discussion of risks and uncertainties is available in our most recent Annual Report filed with the Securities and Exchange Commission (SEC) on Form 10-K and all subsequent SEC filings. Copies of filings made with the SEC are available through the SEC's electronic data gathering analysis retrieval system (EDGAR) at www.sec.gov. We undertake no obligation following the date of this release to update or revise our forward-looking statements or to update the reasons actual results could differ materially from those anticipated in forward-looking statements. We caution you not to place undue reliance upon any such forward-looking statements, which speak only as of the date such statements are made. Past performance is not indicative of future results. We cannot guarantee any future operating results, activity, performance, or achievement.
Source: Ventana Medical Systems
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
